Previous 10 | Next 10 |
Curis Provides Fourth Quarter 2023 Business Update PR Newswire Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host confer...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...
2024-02-07 11:17:34 ET More on Curis Seeking Alpha’s Quant Rating on Curis Historical earnings data for Curis Financial information for Curis Read the full article on Seeking Alpha For further details see: Curis Q4 2023 Earnings Preview
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 PR Newswire LEXINGTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948)...
2024-01-24 12:48:28 ET More on Mid-day movers $ stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript Sight Sciences says Q4 total revenue i...
2024-01-12 21:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-30 08:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study PR Newswire LEXINGTON, Mass. , Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally availabl...
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference PR Newswire LEXINGTON, Mass. , Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an ...
Curis Announces Three Presentations at ASH PR Newswire LEXINGTON, Mass. , Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, to...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...